Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:
“[JUST IN] Final Overall Survival results from the APHINITY trial to be presented at ESMOBreast25
11.3 years of follow-up now confirms what we hoped for:
Adding Pertuzumab to standard Trastuzumab + chemotherapy leads to a statistically significant OS benefit in high-risk HER2+ early breast cancer.
KEY RESULTS
Overall Survival (OS):
HR 0.83 (95% CI: 0.69–1.00), p = 0.044
10-year OS: 91.6% (Pertuzumab) vs 89.8% (Placebo)
Absolute gain: 1.8%
Invasive Disease-Free Survival (IDFS):
HR 0.79 (95% CI: 0.68–0.92)
10-year IDFS: 87.2% vs 83.8%
Absolute gain: 3.4%
Subgroup Analysis: OS
Node-positive: HR 0.79
Node-negative: HR 0.99 No benefit
HR-positive: HR 0.76
HR-negative: HR 0.94 No benefit
Subgroup Analysis: IDFS
Node-positive: HR 0.74
Node-negative: HR 1.01 No benefit
HR-positive: HR 0.75
HR-negative: HR 0.87 Not statistically significant
Safety:
Primary cardiac events <1%
No new long-term cardiac concerns
Take-home message:
Pertuzumab remains the standard of care in node-positive HER2+ early breast cancer
No OS or IDFS benefit in node-negative or HR-negative subgroups
These final long-term data provide clarity on optimal patient selection
Kudos to the APHINITY investigators for delivering decade-long data that refines our approach to HER2+ disease.”
More posts featuring Amol Akhade
